Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

SAPT after TAVR linked to key benefits over DAPT, new data confirm
All-cause mortality after six months was significantly lower for patients discharged on SAPT. That trend remained in place after 24 months.
American Heart Association takes on cardiac amyloidosis with new initiative
One of the project's biggest goals is helping clinicians identify patients in need of care earlier than ever.
Have clinicians been wrong about how they diagnose PAD?
The ankle-brachial index, a noninvasive diagnostic test for peripheral artery disease, may provide even more value than clinicians previously realized.
Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis
Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.
Tech breakthroughs, new policies help cardiologists perform more concomitant EP procedures
Devi Nair, MD, spoke to Cardiovascular Business about her own experience using concomitant LAA occlusion as an add-on to catheter ablation procedures.

SAPT after TAVR linked to key benefits over DAPT, new data confirm

All-cause mortality after six months was significantly lower for patients discharged on SAPT. That trend remained in place after 24 months.

Video of Mathew S. Maurer, MD, director, Cardiac Amyloidosis Program, NewYork Presbyterian Hospital, explains how the American Hearty Association’s ATTR Amyloidosis Initiative is bringing together multidisciplinary teams to strengthen management of transthyretin amyloid cardiomyopathy (ATTR-CM). The goal is to catch more of these patients earlier and ensure they get timely care before they end up in advanced heart failure. #ATTR #Cardiacamyloidosis

American Heart Association takes on cardiac amyloidosis with new initiative

One of the project's biggest goals is helping clinicians identify patients in need of care earlier than ever.

Have clinicians been wrong about how they diagnose PAD?

The ankle-brachial index, a noninvasive diagnostic test for peripheral artery disease, may provide even more value than clinicians previously realized.

Conduction system pacing after TAVR linked to improved outcomes in new meta-analysis

Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.

Devi Nair, MD, director of electrophysiology and research, St. Bernards Medical Center and Arrhythmia Research Group, explains how she uses concomitant left atrial appendage occlusion during EP procedures, and talks about new LAAO devices and ICE imaging.

Tech breakthroughs, new policies help cardiologists perform more concomitant EP procedures

Devi Nair, MD, spoke to Cardiovascular Business about her own experience using concomitant LAA occlusion as an add-on to catheter ablation procedures.

Kenneth Bilchick, MD, MS, Director of Electrophysiology Research, and a professor of cardiovascular medicine at the University of Virginia, explains GLP-1 receptor agonists (GLP-RAs) may do more than drive weight loss—showing a significantly lower risk of atrial fibrillation.

Inflammation may help explain how GLP-1 drugs prevent AFib

Kenneth Bilchick, MD, spoke to Cardiovascular Business about new data he presented at Heart Rhythm 2026.

How TAVR valve implant depth impacts clinical outcomes

TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.

Jupiter Endovascular's Vertex Pulmonary Embolectomy System showed positive results in its SPIRARE II pivotal trial.

'Compelling' study shows promise of new pulmonary embolectomy system

"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.